EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Epidarex Capital Portfolio Company, Confluence Life Sciences, Acquired by Aclaris Therapeutics
August 10, 2017 – Epidarex Capital (“Epidarex”), an early stage life science venture capital firm, is pleased to announce the latest exit from its portfolio with
Aclaris Therapeutics Acquires Confluence Life Sciences, Inc.
Expands pipeline of medicines for the potential treatment of patients with autoimmune disorders. Malvern, PA, August 8, 2017 – Aclaris Therapeutics, Inc. (“Aclaris”) (NASDAQ: ACRS),
Positive Data from APL-2 Studies Show Rapid and Durable Improvements in LDH and Hemoglobin Levels in PNH
Louisville, KY, June 29, 2017 – Apellis Pharmaceuticals, Inc. today provided an update on clinical outcomes in its two ongoing Phase 1b clinical trials with
Groundbreaking Research Into Kinases Using CellOPTIQ From Clyde Biosciences
Highlights from the publication include: Collaboration with AZ on kinase inhibitor induced cardiotoxicity Understanding E-C coupling is essential in kinase research CellOPTIQ® is the only
IGEM Therapeutics Completes Initial Closing of Series A Financing; Appoints CEO
Raises £2 million from Epidarex Capital to progress pipeline of IgE antibody drug candidates to treat cancer IgE antibodies shown to offer greater efficacy than
Mironid is Delighted to Announce the Appointment of Dr Michael Moore PhD, DSc, FRCPath as Non-Executive Director
Dr Moore was Founder Chairman of Mission Therapeutics and PsiOxus Therapeutics with each of which he continues to serve as a non-executive director. He also
Apellis Receives EMA Orphan Drug Designation for APL-2 in PNH
C3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience
Enterprise Therapeutics Receives Funding from Cystic Fibrosis Trust
Brighton, UK, April 5, 2017 – Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of